We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Universal Mask-Wearing Could Increase Population-Wide COVID-19 Immunity, Say Researchers

By HospiMedica International staff writers
Posted on 15 Sep 2020
Even as the world awaits a COVID-19 vaccine, academics have suggested that universal mask-wearing could become a form of inoculation that would generate immunity against the novel coronavirus.

According to a report by the Sunday Telegraph, face masks could be inadvertently making people immune to COVID-19 and less sick from SARS-CoV-2. More...
In a commentary published in the New England Journal of Medicine, academics have proposed that universal face mask wearing could be reducing the severity of coronavirus and increasing the number of new asymptomatic infections.

Earlier research has suggested that the “infectious dose” or the amount of virus a person is exposed to during the start of infection determines the severity of the illness. In August, a large study published in the Lancet showed that “viral load at diagnosis” was an “independent predictor of mortality” in hospital patients. As a result, wearing a mask could lower the infectious dose that the wearer is exposed to and reduce the impact of the disease, as the mask filters out some of the virus-containing droplets. Based on this theory, the researchers have suggested that population-wide mask wearing could ensure a higher proportion of asymptomatic COVID-19 patients.

Additionally, recent research has revealed that even mild or asymptomatic coronavirus infection can induce strong immune responses. This means that if mask wearing reduces the severity of the coronavirus then it is also likely to increase population-wide immunity, as a low viral load can be sufficient to generate an immune response, which is what a vaccine would also do, according to the Sunday Telegraph report.

“This idea of 'variolation' - a term originally derived from the smallpox pre-vaccine era - is quite feasible and may add to the protective physical effects of universal masking - by low level stimulation of the wearer's immune system as it is exposed to low levels of airborne SARS-CoV-2, which can induce an immune response but without any overt infection and disease,” Dr. Monica Gandhi, an infectious disease physician at the University of California, San Francisco, and one of the paper’s authors, told the Sunday Telegraph. “This is after all the response to a typical vaccine - where the recipient's immune systems are stimulated, subclinically, to produce protective immune responses to combat the infection if exposed at a future date.”



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.